Dermatologic conditions in patients of color who are pregnant

C. Jeon, BS a,⁎, O. Agbai, MD b, D. Butler, MD c, J. Murase, MD a,d

a Department of Dermatology, University of California, San Francisco, San Francisco, CA
b Department of Dermatology, University of California–Davis, Sacramento, CA
c Department of Dermatology, Brigham and Women's Hospital, Boston, MA
d Department of Dermatology, Palo Alto Foundation Medical Group, Mountain View, CA

Abstract

Certain dermatoses that present during pregnancy have a predilection for populations with skin of color (SOC). Additionally, certain systemic diseases such as systemic lupus erythematosus tend to be more aggressive during pregnancy and confer worse prognoses in women with SOC. The purpose of this review is to highlight the unique implications of selected diseases during pregnancy as it relates to SOC. Dermatologists should be vigilant for the unique clinical variations of dermatological conditions in patients of color who are pregnant to ensure correct diagnoses and optimize treatment outcomes.

© 2017 The Author(s). Published by Elsevier Inc. on behalf of Women's Dermatologic Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Certain dermatoses that present during pregnancy have a predilection for populations with skin of color (SOC). Additionally, certain systemic diseases such as systemic lupus erythematosus (SLE) tend to be more aggressive during pregnancy and confer worse prognoses in women with SOC. This review highlights the unique implications of selected diseases during pregnancy as it relates to SOC.

Connective tissue changes

Striae gravidarum (SG) is the most common connective tissue change during pregnancy and is more common in women with black, Hispanic, or Asian ethnicities (Chang et al. 2004). The clinical evolution of SG starts with immature, red striae (striae rubra [SR]) that progress to mature, white striae (striae alba [SA]). In the SOC population, the hue of the striae can be more darkly pigmented (striae nigra [SN]) and there may be absence of SR, or the color can be a combination of hyperpigmentation and erythema (Fig. 1). Dermoscopy shows hypermelanosis of the epidermal rete ridges that transversally crosses lesions in a ladder-like fashion in SN but minimal melanosis is observed in SA (Piérard-Franchimont et al. 2005).

There is no strong evidence that topical treatments are effective to prevent SG (Brennan et al. 2012) although there is limited evidence on the use of over-the-counter remedies such as centella and bitter almond oil (Korgavkar and Wang 2015). The treatment approach should be based on the stage of striae (SR vs SA). Postpartum, topiramate, retinoid (pregnancy category C) and SG (Rangel et al. 2001) but no studies have been done exclusively in a SOC population. Products that contain glycolic acid improve SA in patients with skin types I through V (Ash et al. 1998).

Various lasers have become popular as a therapeutic alternative but all have a risk of causing hyperpigmentation. A 585-nm pulsed dye laser (PDL) can be beneficial but should be avoided or used with great caution in patients with skin types IV through VI (Jiménez et al. 2003; Nouri et al. 1999). Non-ablative fractional lasers (1540-nm, 1550-nm, and 1560-nm) can be beneficial, but whether they are more beneficial to treat SR versus SA is unclear (Graber et al. 2008; Malekzad et al. 2014; Stotland et al. 2008; Tretti Clementoni and Lavagno 2015). Ablative lasers have a greater risk of causing complications when compared with nonablative lasers and treatment in patients with skin types IV and higher are associated with scarring and hyperpigmentation (Metelitsa and Alster 2010; Savas et al. 2014). Overall, due to the higher risk of hyperpigmentation in the SOC population, patients should be adequately counseled on the risks and benefits of treatment with laser therapy.

Beneficial nonlaser treatments include intense pulsed light (IPL; Hernández-Pérez et al. 2002) and radiation frequency (Manuskiatti...
of pregnancies (McHugh and Laurent 1989). It is most common in women of black, Hispanic, or Asian descent (Grimes 1995).

Prevention includes counseling on sun protection. Topical treatment options are summarized in Table 1. Azelaic acid is a pregnancy category B drug (Intendis 2005) that is generally considered safe to take during pregnancy. Less is known about hydroquinone (pregnancy category C) in terms of safety and it is generally not recommended to be taken during pregnancy (Nussbaum and Benedetto 2006). Topical steroid medications (pregnancy category C) are often mixed with tretinoin and hydroquinone and need to be used with caution in order to not result in steroid-induced acne (Plewig and Kligman 1973).

Postpartum, topical therapy can include hydroquinone, tretinoin, azelaic acid, or topical corticosteroid combinations. Both hyper- and hypopigmentation may be a side effect with combination use (Kligman and Willis 1975) and long-term use of hydroquinone can lead to ochronosis (Katsambas and Antoniou 1995). Chemical peels and laser therapies should be administered with caution in the SOC population due to the risk for postinflammatory hyperpigmentation (PIH; Graber et al. 2008; Inger 2009; Kroumpouzos and Cohen 2001; Malekzad et al. 2014; Metelitsa and Alster 2010; Nouri et al. 1999; Stotland et al. 2008; Tretti Clementoni and Lavagno 2015). Botanicals such as Chinese herbs and various plant extracts have also become increasingly popular (Fisk et al. 2014).

Dermatoses of pregnancy

Intrahepatic cholestasis of pregnancy

Higher incidence of intrahepatic cholestasis of pregnancy (ICP) has been noted in certain groups with SOC including American Indian (Reyes et al. 1978), Indian, and Pakistani populations (Abedin et al. 1999). Although ICP resolves with delivery, untreated ICP can lead to fatal fetal outcomes (Rioseco et al. 1994); thus, a timely diagnosis is important. Pruritus without rash is common and characteristic but clinical jaundice only occurs in approximately 10% to 15% of patients (Lunzer 1989). Jaundice may not be apparent or reliable on the basis of an examination of the skin in patients with SOC; thus, an assessment should focus on the sclera of eyes, hard palate, palms of the hand, and soles of the feet to identify yellow discoloration. It is important to note that the diagnosis of ICP is not made on the basis of clinical findings but by confirmation of elevated serum bile acid and/or elevated aminotransferase levels (Pusl and Beuvers 2007). Thus, laboratory tests should be considered for any woman who is pregnant and suspected of having ICP such as those

---

Fig. 1. A 35-year-old Chinese female who experienced polymorphic eruption of pregnancy that presented with striae on her thighs postpartum, which was likely the result of the pregnancy and the use of topical steroid medications.
patients with the symptomology of pruritus but without evidence of primary lesions.

**Polymorphic eruption of pregnancy**

Polymorphic eruption of pregnancy (PEP), formerly known as pruritic urticarial papules and plaques of pregnancy, is the most common dermatosis during pregnancy in the Indian population (Kumari et al. 2007). PEP poses no risk to maternal and fetal outcomes during pregnancy (Yancey et al. 1984) and rarely recurs (Ambros-Rudolph and Black 2008). Erythematous papules within abdominal striae with periumbilical sparing are an early finding (Fig. 2; Aronson et al. 1998). White halos that typically surround these papules are less common in populations with a darker skin (Roger et al. 1994). Topical corticosteroid medications with mild-to-moderate potency and oral antihistamines to control symptoms of pruritus may benefit patients during pregnancy (Ambros-Rudolph 2011; Ambros-Rudolph and Shornick 2008). Patients with more severe disease and significant pruritus can be safely treated with a short course of systemic corticosteroid medications (Ambros-Rudolph and Shornick 2008).

**Special considerations**

**Acne vulgaris**

Acne vulgaris is the most common dermatologic condition in patients with SOC (Vaughan Jones et al. 2014). Acne often worsens during the third trimester of pregnancy due to increased maternal androgen concentrations and the resultant effects on sebum

---

**Table 1**

Most commonly used postpartum topical agents for melasma.

| Agent                  | Pregnancy Category | Recommended Prescribing Method                                                                 | Adverse Event(s)                                                                 |
|------------------------|--------------------|-------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Azelaic acid<sup>a</sup> | B                  | Azelaic acid 20% cream or 15% gel (20% concentration of azelaic acid equivalent to 4% hydroquinone in some studies but with fewer side effects) | Erythema, burning, scaling, and pruritus                                          |
| Hydroquinone<sup>b</sup> | C                  | Most effective as combination therapy: triple-combination cream contains hydroquinone 4%, tretinoin 0.05%, and mid-potency topical corticosteroid (fluocinolone acetonide 0.01%) | Most commonly erythema, stinging, and desquamation. Dose and duration dependent effects – irritant contact dermatitis, hypopigmentation of surrounding skin, and, rarely, exogenous ochronosis |
| Topical corticosteroid medications<sup>c</sup> | C                  | Most effective as combination therapy, as noted above.                                         | Irritation, rosacea-like dermatitis, atrophy, telangiectasia, hypertrichosis, and steroid-induced acne |
| Tretinoin<sup>d</sup>  | C                  | Most effective as combination therapy, as noted above.                                         | Most commonly erythema, stinging, and desquamation, postinflammatory hyper- and hypopigmentation |

<sup>a</sup> Balina and Graupe 1991; Intendis 2005; Lynde et al. 2006.  
<sup>b</sup> Chan et al. 2008; Nussbaum and Benedetto 2006; Taylor et al. 2003.  
<sup>c</sup> Bandyopadhyay 2009; Plewig and Kligman 1973.  
<sup>d</sup> Shapiro et al. 1997.
production (Vaughan Jones et al. 2014). Pregnancy-associated immunologic processes may also contribute to the course of disease (Pugashetti and Shinkai 2013). Although there is no unique presentation of acne during pregnancy, in patients with SOC the sequela of PIH, keloids, and severe scarring are common (Coley and Alexis 2009; Davis and Callender 2010; Taylor et al. 2002). Thus, early and aggressive control of the disease process is imperative. To treat patients during pregnancy, topical azelaic acid can be recommended for mild acne with noninflammatory lesions. For inflammatory lesions, a combination with topical erythromycin or clindamycin is recommended. Moderate-to severe inflammatory acne can be managed with oral amoxicillin or medications with cephalosporin such as cefadroxil or cephalaxin. With regard to fulminant nodular cystic acne, a course of oral prednisolone that lasts no longer than a month may be appropriate after the first trimester (Chien et al. 2016). Patient education is important to prevent the excoriation of acne lesions, harsh skin regimen, and cultural skin and hair care practices by the patient that can either worsen acne or cause PIH or scarring (Taylor et al. 2002).

Vitiligo, psoriasis, and atopic dermatitis

The etiology of vitiligo is thought to be multifactorial and no increase in incidence during pregnancy has been reported (Njoo and Westerhof 2001; Papadopoulos et al. 1998). Although not associated with adverse outcomes during pregnancy (Horev et al. 2011), vitiligo can be particularly distressing in patients with SOC due to its obvious presentation in contrast to darker skin tones and hyperpigmentation during pregnancy may exaggerate this contrast.

Psoriasis, a common diagnosis in non-white populations (Davis et al. 2012), improves in approximately half and worsens in approximately one fourth of patients. In patients whose condition improves, the reduction of lesions is marked and approximately 80% to 90% of lesions clear from the first to the third trimester (Boyd et al. 1996; Murase et al. 2005). In the population with SOC, the presentation may be subtler with lesions that appear more violaceous than red (Fig. 3A) and less prominent scaling (Fig. 3B).

An atopic dermatitis (AD) flare during pregnancy, which is also known as atopic eruption of pregnancy, is the most common dermatosis during pregnancy and accounts for 36% to 50% of cases. It is the second most common skin disease in patients of black race (Halter et al. 1983). Furthermore, in women with SOC who are pregnant, AD is more likely to present with hypopigmented lichenified patches and plaques and the erythema may be more difficult to visualize (Fig. 4).

Ultraviolet B phototherapy may be considered as a management option for the above conditions. However, photodegradation of folic acid is associated with light therapy; thus, to mitigate the risk of folate deficiency during the first trimester, it is important for the mother to supplement with 0.4 mg to 1 mg of folic acid per day (Park and Murase 2012). Currently, there is no consensus on the appropriate folate supplementation during phototherapy (Murase et al. 2010) and patients who are at high risk may require up to 5 mg daily (Wilson et al. 2003). Of important note, vitamin B12 deficiency must be ruled out if a patient supplements with more than 1 mg per day because vitamin B12 deficiency and high serum folate are associated with an increased risk of cognitive impairment and anemia in adults (Selhub et al. 2007). Also, patients with SOC are at a higher risk of melasma during pregnancy so photoprotection of the face is important during light therapy (Sharquie et al. 2008).

Systemic lupus erythematosus, sarcoidosis, and scleroderma

SLE is more prevalent in women of black race compared with other populations (Clowse et al. 2008). Disease flares increase during pregnancy and usually present with dermatologic manifestations (Figs. 5A and B; Clowse 2007). Specifically, the discoid lupus erythematosus (DLE) subtype presents with erythematous plaques and scaling that becomes atrophied with excessive scarring with borders

---

**Fig. 3.** A 34-year-old Indian woman with chronic plaque psoriasis who begins to experience a flare of her psoriasis after the birth of her child. (A) Plaques that were clear during the pregnancy have recurred on her leg. (B) Thin psoriasis form plaques that begin to form on the right upper back after her back had been clear for the majority of the pregnancy. The areas that were clear during the pregnancy are present as faint patches of postinflammatory pigmentation that cover the back.

**Fig. 4.** A 30-year-old Chinese patient who presented with atopic eruption of pregnancy (AEP) during the first trimester of her pregnancy. Note that the dark hyperpigmentation masks the hue of erythema that is present on the nipples, which are some of the most vulnerable areas of the body to AEP.
of PIH in patients of SOC but Caucasian patients rarely present with PIH (McCauliffe 2001; Nozile et al. 2015; Rothfield et al. 2006). This leads to a significant contrast between normal and lesional skin particularly in populations of SOC. In addition, individuals of African descent may show dark, blue-black nail dyschromia (Vaughan Jones et al. 2014). Although DLE increases the risk for squamous cell carcinoma (Hordinsky 1997), SLE carries a higher risk of spontaneous abortion, fetal death, preterm delivery, and intrauterine growth restriction that is secondary to antiphospholipid syndrome, lupus nephritis, or hypertension (Chakravarty et al. 2006).

Sarcoidosis is also seen more commonly in women of black race (Rybicki et al. 1997). Both specific and nonspecific cutaneous lesions are associated with sarcoidosis during pregnancy and women of black race most commonly present with papular lesions (Minus and Grimes 1983). In patients with SOC, plaques can develop hypopigmentation (Elgart 1986). Plaques are more likely to cause permanent scarring compared with papular lesions (Hanno and Grimes 1983). In patients with SOC, plaques can develop hypopigmentation and most commonly in the areas of the hands, arms, and trunk (Adelowo and Oguntona 2009; Ee and Tan 2005; Halder et al. 2003). Diffuse hyperpigmentation may also be present (Steens 1998). Pigmented changes are one of the most common cutaneous manifestations in patients of black race (Kuwana et al. 1999; Reveille et al. 2001). Diffuse or active disease can lead to maternal renal crisis as well as prematurity and small full-term infants (Rabhi et al. 2002).

There are no treatment options available exclusively for patients with SOC for these conditions. Early detection of disease activity as well as patient education on disease activity and risk of complications with pregnancy are paramount. Clinicians and particularly dermatologists should ask general screening questions during the early phase of pregnancy with regard to common rheumatologic disease skin manifestations, especially in the case of patients with SOC (Spinillo et al. 2012).

**Conclusion**

Certain dermatologic conditions during pregnancy are more common in women with SOC and often present with unique clinical manifestations. Treatment options for these conditions are limited and management can be difficult, particularly for women in these populations. Thus, dermatologists should be vigilant for variations in clinical findings for patients with SOC to ensure correct and timely diagnoses and optimize treatment outcomes for these patients.

**References**

Abedin P, Weaver JB, Egginton E. Intrahepatic cholestasis of pregnancy: Prevalence and ethnic distribution. Ethn Health 1999;4:35–7.

Adelowo OO, Oguntona S. Scleroderma (systemic sclerosis) among Nigerians. Clin Rheumatol 2008;28:1121–5.

Alam M, Posen W, Martini MC, Wrone DA, Radermaker AW. Aesthetic and functional efficacy of subcuticular running epidermal closures of the trunk and extremity: A rater-blinded randomized control trial. Arch Dermatol 2006;142:1272–8.

Albertini JC, Tyler W, Miller OF. Ultracutaneous sarcoidosis. Case report and review of the literature. Arch Dermatol 1997;133:215–9.

Alderdice F, McKenna D, Dornan J. Techniques and materials for skin closure in caesarian section. Cochrane Database Syst Rev 2003;CD003577.

Alexiadis-Armenakas MR, Bernstein LJ, Friedman PM, Geromonous RG. The safety and efficacy of the 308-nm excimer laser for pigment correction of hypopigmented scars and striae alba. Arch Dermatol 2004;140:955–60.

Ambros-Rudolph CM, Scher AJ. Black M. Polymorphic eruption of pregnancy. Obstetric and Gynecologic Dermatology. 3rd ed. London: Elsevier Health Sciences; 2008. p. 49–55.

Ambros-Rudolph CM, Scher AJ. Pregnancy dermatoses. Dermatol Clin. 2nd ed. London: Elsevier; 2008. p. 1119–20.

Ambros-Rudolph CM. Dermatoses of pregnancy – clues to diagnosis, fetal risk and therapy. Ann Dermatol 2011;23:285–75.

Aronson IK, Bond S, Fiedler VC, Vomvouras S, Gruber D, Ruiz C. Pruritic urticarial papules and plaques of pregnancy: clinical and immunopathologic observations in 57 patients. J Am Acad Dermatol 1998;39:933–9.

Ash K, Lord J, Zukowski M, McDaniel DH. Comparison of topical therapy for striae alba (20% glycolic acid/0.05% tretinoin versus 20% glycolic acid/10% L-ascorbic acid). Dermatol Surg 1998;24:840–56.
Rioseco AJ, Ivanovic MB, Manzur A, Hamed F, Kato SR, Parer JT, et al. Intrahepatic cholestasis of pregnancy: A retrospective case-control study of perinatal outcome. Am J Obstet Gynecol 1994;170:890–5.

Rogier D, Vaillant L, Fignon A, Pierre F, Baey Y, Brechot JF, et al. Specific pruritic diseases of pregnancy. A prospective study of 3192 pregnant women. Arch Dermatol 1994;130:734–9.

Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: Systemic and cutaneous manifestations. Clinics in Dermatol 2006:24:348–62.

Rybicki BA, Major M, Popovich J, Malarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: A 5-year study in a health maintenance organization. Am J Epidemiol 1997;145:234–41.

Sadick NS, Magro C, Hoening A. Prospective clinical and histological study to evaluate the efficacy and safety of a targeted high-intensity narrow band UVB/UVA1 therapy for striae alba. J Cosmet Laser Ther 2007;9:79–83.

Savas JA, Ledon JA, Franca K, Nouri K. Lasers and lights for the treatment of striae distensae. Lasers Med Sci 2014;29:1735–43.

Selhub J, Morris MS, Jacques PF. In vitamin B12 deficiency, higher serum folate is associated with increased total homocysteine and methylmalonic acid concentrations. Proc Natl Acad Sci U S A 2007;104:19995–20000.

Shapiro L, Pautzsek A, Curto G, Koren G. Safety of first-trimester exposure to topical tretinoin: Prospective cohort study. Lancet 1997:350:1143–4.

Sharquie KE, Al-Mashhadani SA, Salman HA. Topical 10% zinc sulfate solution for treatment of melasma. Dermatol Surg 2008;34:1346–9.

Shridharani SM, Magarakis M, Pineda ME, et al. Pregnancy and sarcoidosis: An insight into the pathogenesis of hypercalciuria. Chest 2004;126:995–8.

Taylor SC, Cook-Bolden F, Rahman Z, Strachan D. Acne vulgaris in skin of color. J Am Acad Dermatol 2002;46:958–106.

Taylor SC, Torok H, Jones T, Lowe N, Rich P, Tschen E, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis 2003;72:67–72.

Tretti Clementoni M, Lavagno R. A novel 1565 nm non-ablative fractional device for stretch marks: A preliminary report. J Cosmet Laser Ther 2013;17:148–55.

Tulandi T, Al-Sannan B, Akbar G, Ziegler C, Miner L. Prospective study of intraabdominal adhesions among women of different races with or without keloids. Am J Obstet Gynecol 2011;204:132.e1–4.

Vaughan Jones S, Ambros-Rudolph C, Nelson-Piercy C. Skin disease in pregnancy. BMJ 2014;348:g3489.

Wilson RD, Davies G, Desilets V, Reid GJ, Summers A, Wyatt P, et al. The use of folic acid for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can 2003;25:959–73.

Wolfram D, Tzankov A, Pülzl P, Piza-Katzer H. Hypertrophic scars and keloids–a review of their pathophysiology, risk factors, and therapeutic management. Dermatol Surg 2009;35:171–81.

Yancey KB, Hall RP, Lawley TJ. Pruritic urticarial papules and plaques of pregnancy. Clinical experience in twenty-five patients. J Am Acad Dermatol 1984;10:473–80.